Recent research suggested that sodium-glucose cotransporter-2 (SGLT-2) inhibitors can mitigate memory impairment linked to Alzheimer’s disease and are now being explored for their cognitive benefits. This evidence concerns the gene SLC5A2 and early-onset autosomal dominant Alzheimer disease.